Press Releases

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration...

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

bioMérieux, a world leader in the field of in vitro diagnostics, is announcing the forthcoming launch of 3 different tests to address the COVID-19 epidemic and to meet the different needs of physician...

2019 Financial Results

€2,675 million in sales for full-year 2019, representing a reported increase of 10.5% and organic growth of 7.2% Strong sales momentum in the fourth quarter, with organic growth of 8.3% driven by sale...

Financial Information

Résultats annuels au 31 décembre 2019

Chiffre d’affaires 2019 de 2 675 millions d’euros, en hausse de 10,5 % à données publiées, soit une croissance organique de 7,2 % Solide dynamique commerciale au 4e trimestre, avec une croissance orga...

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clear...

bioMérieux and the Fleming Fund: working together to strengthen diagnostic capacity and tackle antimicrobial resistance in low- and middle-income countries

London (UK), Marcy l’Étoile (France) – December 18, 2019 – bioMérieux, a world leader in in vitro diagnostics which develops and manufactures testing solutions (systems, reagents, software, services) ...